Welcometo Issue 41 of Breast Cancer Research Review.
- Published in:
- Breast Cancer Research Review, 2023, n. 41, p. 1
- By:
- Publication type:
- Article
Works matching IS 11794976 AND DT 2023
Results: 12
1
2
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases.
- Published in:
- Breast Cancer Research Review, 2023, n. 40, p. 5
- By:
- Publication type:
- Article
3
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1).
- Published in:
- Breast Cancer Research Review, 2023, n. 40, p. 5
- By:
- Publication type:
- Article
4
Genomics to select treatment for patients with metastatic breast cancer.
- Published in:
- Breast Cancer Research Review, 2023, n. 40, p. 5
- By:
- Publication type:
- Article
5
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA).
- Published in:
- Breast Cancer Research Review, 2023, n. 40, p. 4
- By:
- Publication type:
- Article
6
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03.
- Published in:
- Breast Cancer Research Review, 2023, n. 40, p. 4
- By:
- Publication type:
- Article
7
Chemotherapy refusal and subsequent survival in healthy older women with high genomic risk estrogen receptor-positive breast cancer.
- Published in:
- Breast Cancer Research Review, 2023, n. 40, p. 3
- By:
- Publication type:
- Article
8
A systematic review of the impact of the COVID-19 pandemic on breast cancer screening and diagnosis.
- Published in:
- Breast Cancer Research Review, 2023, n. 40, p. 3
- By:
- Publication type:
- Article
9
Australian women’s responses to breast density information: A content analysis.
- Published in:
- Breast Cancer Research Review, 2023, n. 40, p. 3
- By:
- Publication type:
- Article
10
Survival outcomes and care equity among patients with advanced breast cancer in Auckland, New Zealand.
- Published in:
- Breast Cancer Research Review, 2023, n. 40, p. 2
- By:
- Publication type:
- Article
11
Sentinel lymph node biopsy alone is adequate for chemotherapy decisions in postmenopausal early-stage hormone-receptor-positive, HER2-negative breast cancer with one to three positive sentinel lymph nodes.
- Published in:
- Breast Cancer Research Review, 2023, n. 40, p. 1
- By:
- Publication type:
- Article
12
Welcome to the 40th issue of Breast Cancer Research Review.
- Published in:
- Breast Cancer Research Review, 2023, n. 40, p. 1
- By:
- Publication type:
- Article